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Table 1. Absolute (mg) and body weight adjusted (mg/g) liver and kidney weights in normal and uremic rats
Treatment group Body weight (g)a Liver wt (mg) Liver wt (mg/g) Kidney wt (mg) Kidney wt (mg/g)
La[−] control 472 11,632 24.6 1489 3.2
La[+] control 463 11,004 23.8 1430 3.1
La[−] adenine 340 9003 26.5 2420 7.1
La[+] adenine 307 7114 23.2 2092 6.8
La[−] Nx 330 8899 27.0 810 2.5
La[+] Nx 307 7829 25.5 727 2.4
Abbreviations: [−], no lanthanum treatment; [+], 3% lanthanum in diet; Nx, 5/6th nephrectomized renal failure model; adenine, adenine induced renal failure model
(adenine given 0.3% of diet); control, normal renal function. Body weight adjustment abolishes differences in organ weight between lanthanum-treated and -untreated
groups within each renal failure model.
aNonfasted preterminal body weight (day 38) extracted from Figure 1 of Lacour et al [1].
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The need for careful
interpretation of animal data
on lanthanum
To the Editor: Lacour et al [1] describe reductions in
organ weights in uremic rats given lanthanum carbon-
ate, those for liver and kidney being highlighted as sig-
nificant because differences remained after normalisa-
tion for femur length. Adjustment using femur length
is unconventional, as drug effects on body mass (un-
less they affect growth) do not influence this parameter.
Normalization using body mass is the standard method,
and in our view should have been used due to the dif-
ferences in body weight between lanthanum-treated and
-untreated rats. When kidney and liver weights are nor-
malized in this way, group differences are abolished (see
Table 1 above).
The authors also note qualitative differences in tissue
lanthanum deposition between normal and uremic rats,
and between different uremia models. No hypotheses
were put forward to suggest why lanthanum might de-
posit in brain, heart, and skeletal muscle in one disease
model, but not in another, or in normal rats. The extent
to which these differences were artefacts of contamina-
tion is unclear, as lanthanum was administered at very
high concentrations in the diet (probably powdered), and
plasma concentrations were extraordinarily high both in
control and lanthanum-treated groups [2]. Lung depo-
sition is also unusual in our experience and may reflect
inhalation of lanthanum from the diet. Furthermore, the
authors report major intestinal pathology in the adenine
uremia model, but not the nephrectomized model, yet
paradoxically rule out any influence of this on the ab-
sorption and deposition of lanthanum.
Extrapolation of the Lacour et al [1] findings to human
lanthanum exposure appears unwarranted at this time.
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Reply from the Authors
We agree with Rambeck that the usual way of compar-
ing organ weights of uremic animals with those of nor-
mal animals is normalization for body mass, not femur
length. However, because in our study we happened to
observe markedly lower liver weights in the two animal
groups with chronic renal failure (CRF) fed on lanthanum
carbonate, we compared CRF rats receiving lanthanum
treatment with CRF rats receiving no lanthanum treat-
ment [1]. Thus, in doing this analysis we did not compare
CRF rats with normal rats. Because total body weights
were also slightly decreased in the two groups of CRF
rats that received lanthanum supplements, as compared
to those CRF rat groups receiving no lanthanum sup-
plements, we reasoned that the changes in liver weight
should be better normalized using total femur length,
which remained the same, than using total body weight,
